Transsphenoidal microsurgical removal of growth hormone-secreting pituitary adenomas. A review of 137 cases

D. S. Baskin, James E Boggan, C. B. Wilson

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

A series of 137 patients with growth hormone (GH)-secreting pituitary adenomas were treated by transsphenoidal surgery during a 10-year period. Group A comprised patients for whom this surgery was the first therapeutic intervention, and Group B included those who underwent the surgery after previous therapeutic intervention. The results were analyzed considering preoperative and postoperative endocrinological, neurological, ophthalmological, and neuroradiological data. Remission was defined as clinical response and a normal postoperative GH level, and partial remission as clinical response and postoperative reduction of the GH level by more than 50%. Any other result was considered failure. The mean follow-up period was 37.1 months; follow-up review was achieved in all the patients. Among the 102 patients in Group A, remission was achieved in 80 (78%) patients with transsphenoidal surgery alone, and in an additional 16 (16%) after postoperative irradiation (combined response rate, 94%). All failures and patients with partial remission had preoperative GH levels of more than 50 ng/ml and suprasellar extension of the tumor. There were no deaths; 8% of patients had minor surgical morbidity; 5% had new hypopituitarism postoperatively. Of patients subsequently irradiated, 71% developed hypopituitarism. Among the 35 patients in Group B, remission was achieved in 26 (74%), partial remission was obtained in two (6%), and seven (20%) were considered treatment failures. There were no deaths, and the morbidity rate was 14%; 66% of patients had hypopituitarism postoperatively. Of the eight patients who had received prior irradiation only, seven (88%) went into remission. All failures and partial responders had preoperative GH levels greater than 40 ng/ml; 56% had suprasellar extension. These results confirm the efficacy of the transsphenoidal approach for the treatment of GH-secreting pituitary adenomas.

Original languageEnglish (US)
Pages (from-to)634-641
Number of pages8
JournalJournal of Neurosurgery
Volume56
Issue number5
StatePublished - 1982

Fingerprint

Growth Hormone-Secreting Pituitary Adenoma
Hypopituitarism
Growth Hormone
Morbidity
Treatment Failure

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Transsphenoidal microsurgical removal of growth hormone-secreting pituitary adenomas. A review of 137 cases. / Baskin, D. S.; Boggan, James E; Wilson, C. B.

In: Journal of Neurosurgery, Vol. 56, No. 5, 1982, p. 634-641.

Research output: Contribution to journalArticle

@article{0c01df404eab4cc5a39a64339ee4f9e3,
title = "Transsphenoidal microsurgical removal of growth hormone-secreting pituitary adenomas. A review of 137 cases",
abstract = "A series of 137 patients with growth hormone (GH)-secreting pituitary adenomas were treated by transsphenoidal surgery during a 10-year period. Group A comprised patients for whom this surgery was the first therapeutic intervention, and Group B included those who underwent the surgery after previous therapeutic intervention. The results were analyzed considering preoperative and postoperative endocrinological, neurological, ophthalmological, and neuroradiological data. Remission was defined as clinical response and a normal postoperative GH level, and partial remission as clinical response and postoperative reduction of the GH level by more than 50{\%}. Any other result was considered failure. The mean follow-up period was 37.1 months; follow-up review was achieved in all the patients. Among the 102 patients in Group A, remission was achieved in 80 (78{\%}) patients with transsphenoidal surgery alone, and in an additional 16 (16{\%}) after postoperative irradiation (combined response rate, 94{\%}). All failures and patients with partial remission had preoperative GH levels of more than 50 ng/ml and suprasellar extension of the tumor. There were no deaths; 8{\%} of patients had minor surgical morbidity; 5{\%} had new hypopituitarism postoperatively. Of patients subsequently irradiated, 71{\%} developed hypopituitarism. Among the 35 patients in Group B, remission was achieved in 26 (74{\%}), partial remission was obtained in two (6{\%}), and seven (20{\%}) were considered treatment failures. There were no deaths, and the morbidity rate was 14{\%}; 66{\%} of patients had hypopituitarism postoperatively. Of the eight patients who had received prior irradiation only, seven (88{\%}) went into remission. All failures and partial responders had preoperative GH levels greater than 40 ng/ml; 56{\%} had suprasellar extension. These results confirm the efficacy of the transsphenoidal approach for the treatment of GH-secreting pituitary adenomas.",
author = "Baskin, {D. S.} and Boggan, {James E} and Wilson, {C. B.}",
year = "1982",
language = "English (US)",
volume = "56",
pages = "634--641",
journal = "Journal of Neurosurgery",
issn = "0022-3085",
publisher = "American Association of Neurological Surgeons",
number = "5",

}

TY - JOUR

T1 - Transsphenoidal microsurgical removal of growth hormone-secreting pituitary adenomas. A review of 137 cases

AU - Baskin, D. S.

AU - Boggan, James E

AU - Wilson, C. B.

PY - 1982

Y1 - 1982

N2 - A series of 137 patients with growth hormone (GH)-secreting pituitary adenomas were treated by transsphenoidal surgery during a 10-year period. Group A comprised patients for whom this surgery was the first therapeutic intervention, and Group B included those who underwent the surgery after previous therapeutic intervention. The results were analyzed considering preoperative and postoperative endocrinological, neurological, ophthalmological, and neuroradiological data. Remission was defined as clinical response and a normal postoperative GH level, and partial remission as clinical response and postoperative reduction of the GH level by more than 50%. Any other result was considered failure. The mean follow-up period was 37.1 months; follow-up review was achieved in all the patients. Among the 102 patients in Group A, remission was achieved in 80 (78%) patients with transsphenoidal surgery alone, and in an additional 16 (16%) after postoperative irradiation (combined response rate, 94%). All failures and patients with partial remission had preoperative GH levels of more than 50 ng/ml and suprasellar extension of the tumor. There were no deaths; 8% of patients had minor surgical morbidity; 5% had new hypopituitarism postoperatively. Of patients subsequently irradiated, 71% developed hypopituitarism. Among the 35 patients in Group B, remission was achieved in 26 (74%), partial remission was obtained in two (6%), and seven (20%) were considered treatment failures. There were no deaths, and the morbidity rate was 14%; 66% of patients had hypopituitarism postoperatively. Of the eight patients who had received prior irradiation only, seven (88%) went into remission. All failures and partial responders had preoperative GH levels greater than 40 ng/ml; 56% had suprasellar extension. These results confirm the efficacy of the transsphenoidal approach for the treatment of GH-secreting pituitary adenomas.

AB - A series of 137 patients with growth hormone (GH)-secreting pituitary adenomas were treated by transsphenoidal surgery during a 10-year period. Group A comprised patients for whom this surgery was the first therapeutic intervention, and Group B included those who underwent the surgery after previous therapeutic intervention. The results were analyzed considering preoperative and postoperative endocrinological, neurological, ophthalmological, and neuroradiological data. Remission was defined as clinical response and a normal postoperative GH level, and partial remission as clinical response and postoperative reduction of the GH level by more than 50%. Any other result was considered failure. The mean follow-up period was 37.1 months; follow-up review was achieved in all the patients. Among the 102 patients in Group A, remission was achieved in 80 (78%) patients with transsphenoidal surgery alone, and in an additional 16 (16%) after postoperative irradiation (combined response rate, 94%). All failures and patients with partial remission had preoperative GH levels of more than 50 ng/ml and suprasellar extension of the tumor. There were no deaths; 8% of patients had minor surgical morbidity; 5% had new hypopituitarism postoperatively. Of patients subsequently irradiated, 71% developed hypopituitarism. Among the 35 patients in Group B, remission was achieved in 26 (74%), partial remission was obtained in two (6%), and seven (20%) were considered treatment failures. There were no deaths, and the morbidity rate was 14%; 66% of patients had hypopituitarism postoperatively. Of the eight patients who had received prior irradiation only, seven (88%) went into remission. All failures and partial responders had preoperative GH levels greater than 40 ng/ml; 56% had suprasellar extension. These results confirm the efficacy of the transsphenoidal approach for the treatment of GH-secreting pituitary adenomas.

UR - http://www.scopus.com/inward/record.url?scp=0019997561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019997561&partnerID=8YFLogxK

M3 - Article

C2 - 7069474

AN - SCOPUS:0019997561

VL - 56

SP - 634

EP - 641

JO - Journal of Neurosurgery

JF - Journal of Neurosurgery

SN - 0022-3085

IS - 5

ER -